Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Dainippon Sumitomo submitted an NDA to U.S. FDA for its atypical antipsychotic lurasidone for schizophrenia, and the company is hoping its newly acquired Sepracor sales force is up to the challenge in a crowded, but still fruitful, market
You may also be interested in...
Dainippon Sumitomo Pharma Advances Pipeline Despite Setbacks
TOKYO - Osaka-based Dainippon Sumitomo scored a few advances in its pipeline despite an earlier setback for its epilepsy medicine Stedesa (eslicarbazepine) when U.S. FDA asked for additional information last November and extended its PDUFA date 90 days to April 30, the company reported Feb. 3 when it announced earnings results for the April-December period. Stedesa is being developed by Dainippon's new subsidiary Sepracor
Dainippon Sumitomo Pharma Advances Pipeline Despite Setbacks
TOKYO - Osaka-based Dainippon Sumitomo scored a few advances in its pipeline despite an earlier setback for its epilepsy medicine Stedesa (eslicarbazepine) when U.S. FDA asked for additional information last November and extended its PDUFA date 90 days to April 30, the company reported Feb. 3 when it announced earnings results for the April-December period. Stedesa is being developed by Dainippon's new subsidiary Sepracor
Japanese Dainippon Sumitomo Pharma To Acquire Sepracor For $2.6 Billion
The share price of Sepracor surged by over 25 percent to a high of $22.80 before trading was halted mid-day on Sept. 2, amid speculation of an imminent takeover by Japan's Dainippon Sumitomo Pharma